ADM2 (Adrenomedullin 2), also known as intermedin, is a peptide hormone belonging to the calcitonin gene-related peptide (CGRP) family. It shares structural and functional similarities with adrenomedullin (ADM), both playing roles in cardiovascular regulation, fluid homeostasis, and cellular proliferation. ADM2 binds to receptors formed by calcitonin receptor-like receptor (CLR) and receptor activity-modifying proteins (RAMPs), activating signaling pathways like cAMP and MAPK. It is widely expressed in tissues, including the heart, kidneys, and vascular endothelium, and is implicated in vasodilation, anti-inflammatory responses, and tissue protection under hypoxic or ischemic conditions.
ADM2 antibodies are essential tools for detecting and quantifying this peptide in research and diagnostics. They enable studies on ADM2’s involvement in diseases such as hypertension, heart failure, chronic kidney disease, and cancer. Commercially available antibodies (polyclonal or monoclonal) are validated for techniques like ELISA, immunohistochemistry, and Western blot. Their specificity helps clarify ADM2’s pathophysiological roles, including its dual effects in promoting angiogenesis in tumors while protecting against vascular injury. Challenges remain in distinguishing cross-reactivity with ADM due to sequence homology, emphasizing the need for rigorously validated antibodies. Ongoing research explores ADM2 as a potential therapeutic target or biomarker, driving demand for reliable detection tools.